These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31209697)

  • 1. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.
    Armstrong SA; Liu SV
    Adv Ther; 2019 Aug; 36(8):1826-1832. PubMed ID: 31209697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
    Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
    J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab for the treatment of small cell lung cancer.
    Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
    Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
    Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
    Armstrong SA; Liu SV
    Curr Oncol Rep; 2020 Feb; 22(2):20. PubMed ID: 32034529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab: A Review in Extensive-Stage SCLC.
    Frampton JE
    Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
    Mutlu H; Bozcuk H; Artaç M; Eser İ
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S6-S11. PubMed ID: 37147977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
    Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
    Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
    Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
    BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 19. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.